• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

    5/6/25 4:01:00 PM ET
    $ACET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACET alert in real time by email

    Two programs with clinical data readouts in 2H/2025

    Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary clinical data expected in 2H/2025; Trial now open for enrollment to patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE)

    Preliminary data for ongoing ADI-270 Phase 1 clinical trial in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) expected in 2H/2025

    Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2025.

    "We are approaching an exciting inflection point for our pipeline, with significant data milestones on the horizon," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "In the second half of 2025, we expect to report preliminary Phase 1 data from our two lead programs - ADI-001 in autoimmune diseases and ADI-270 in ccRCC, with more than 6 patients with at least 3-month follow up in both programs. As we progress toward these readouts, we also look to harness the full potential of our allogeneic gamma delta 1 CAR T cell therapy platform, which we believe has key advantages over other cell types. We have identified two promising highly differentiated programs, one targeting PSMA and one follow-on program targeting autoimmune diseases with potential to become best-in-class therapies for patients fighting autoimmune diseases and cancer."

    First Quarter 2025 and Recent Operational Highlights:

    Autoimmune diseases

    • Enrollment open for LN and SLE patients in Phase 1 clinical trial of ADI-001 in autoimmune diseases. In April 2025, Adicet expanded enrollment in its Phase 1 trial to include patients with SLE, in addition to ongoing enrollment in LN. The Company expects to initiate enrollment for patients with systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV) in the Phase 1 trial in 3Q/2025. Preliminary clinical data from the trial is expected in 2H/2025, subject to study site initiation and patient enrollment.
    • ADI-001 granted two new Fast Track Designations. In February 2025, the Food and Drug Administration (FDA) granted Fast Track Designation to ADI-001 for the treatment of refractory SLE with extrarenal involvement and for SSc.

    Hematologic malignancies and solid tumor indications

    • Patient enrollment ongoing in Phase 1 trial of ADI-270 in metastatic/advanced ccRCC. Patient enrollment is underway in the Phase 1 clinical trial evaluating ADI-270 in adults with relapsed or refractory metastatic/advanced ccRCC. Adicet expects to share preliminary clinical data from the trial in 2H/2025.
    • Oral presentation of ADI-270 data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting. Adicet will present an oral abstract highlighting strong preclinical data demonstrating ADI-270's anti-tumor activity in hematologic and solid tumor models at the ASGCT Annual Meeting taking place May 13-17, 2025 in New Orleans, LA.
    • Presented ADI-270 preclinical data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting. In March 2025, Adicet presented posters covering preclinical data of ADI-270 at the SITC 2025 Spring Scientific Meeting.

    Corporate Update

    • Appointed Michael Grissinger to Board of Directors. In April 2025, Adicet appointed Michael Grissinger to its Board of Directors. Mr. Grissinger brings over four decades of leadership experience in biopharmaceutical business development, strategy, and M&A to Adicet. Mr. Grissinger has an extensive track record of driving commercial success for global pharmaceutical companies, with a strong focus on immunology. He also serves on the board of directors at Aprea Therapeutics (NASDAQ:APRE) and three privately-held biotechnology companies, Envisagenics, Inc., AnaCardio AB, and NephroDI Therapeutics, Inc.

    Financial Results for First Quarter 2025:

    • Research and Development (R&D) Expenses: R&D expenses were $22.8 million for the three months ended March 31, 2025, compared to $23.9 million during the same period in 2024. The decrease in R&D expenses was primarily due to a net $1.4 million decrease in expenses related to contract development manufacturing organizations and other externally conducted research and development.
    • General and Administrative (G&A) Expenses: G&A expenses were $7.1 and 7.0 million for the three months ended March 31, 2025 and 2024, respectively.
    • Net Loss: Net loss for the three months ended March 31, 2025 was $28.2 million, or a net loss of $0.31 per basic and diluted share, including non-cash stock-based compensation expense of $3.1 million, as compared to a net loss of $28.0 million, or a net loss of $0.35 per basic and diluted share, including non-cash stock-based compensation expense of $5.7 million during the same period in 2024.
    • Cash Position: Cash and cash equivalents were $150.4 million as of March 31, 2025, compared to $176.3 million as of December 31, 2024. The Company expects that current cash, cash equivalents and short-term investments as of March 31, 2025, will be sufficient to fund its operating expenses into the second half of 2026.

    About Adicet Bio, Inc.

    Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

    Forward-Looking Statements

    This press release contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: clinical development of Adicet's product candidates, including future plans or expectations for ADI-001 in autoimmune diseases and ADI-270 in ccRCC and the potential safety, tolerability and efficacy for the treatment of autoimmune diseases and cancer; timing and success of the Phase 1 clinical trial of ADI-001 in LN, SLE, SSc, AAV, IIM and SPS, including timing and expectations for enrollment and future data releases; timing and success of the Phase 1 clinical trial of ADI-270 in ccRCC, including expectations for future data releases; expectations regarding the presentation of preclinical data at future scientific conferences; and expectations regarding Adicet's uses of capital, expenses and financial results, including the expected cash runway.

    Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health emergencies on Adicet's business and financial results, including with respect to disruptions to our preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet's ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet's product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable; and Adicet's ability to meet production and product release expectations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet's actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Adicet's most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Adicet's other filings with the U.S. Securities and Exchange Commission, including its quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.

    ADICET BIO, INC.

    Consolidated Statements of Operations and Comprehensive Income

    (in thousands, except share and per share amounts)

    (Unaudited)

     

     

     

     

     

     

    Three Months Ended March 31,

     

     

     

    2025

     

     

    2024

     

    Operating expenses:

     

     

     

     

     

     

    Research and development

     

    $

    22,814

     

     

    $

    23,897

     

    General and administrative

     

     

    7,071

     

     

     

    6,974

     

    Total operating expenses

     

     

    29,885

     

     

     

    30,871

     

    Loss from operations

     

     

    (29,885

    )

     

     

    (30,871

    )

    Interest income

     

     

    1,683

     

     

     

    2,918

     

    Interest expense

     

     

    —

     

     

     

    (2

    )

    Other expense, net

     

     

    (12

    )

     

     

    (61

    )

    Loss before income tax provision

     

     

    (28,214

    )

     

     

    (28,016

    )

    Income tax provision

     

     

    —

     

     

     

    —

     

    Net loss

     

    $

    (28,214

    )

     

    $

    (28,016

    )

    Net loss per share, basic and diluted

     

    $

    (0.31

    )

     

    $

    (0.35

    )

    Weighted-average common shares used in computing net loss per share, basic and diluted

     

     

    91,071,436

     

     

     

    79,071,652

     

    Other comprehensive income

     

     

     

     

     

     

    Unrealized loss on treasury securities, net of tax

     

     

    (25

    )

     

     

    —

     

    Total other comprehensive income

     

     

    (25

    )

     

     

    —

     

    Comprehensive loss

     

    $

    (28,239

    )

     

    $

    (28,016

    )

    ADICET BIO, INC.

    Consolidated Balance Sheets Information

    (in thousands)

    (Unaudited)

     

     

    March 31,

    December 31,

     

     

    2025

     

     

    2024

     

    Cash, cash equivalents, and short term investments

    in treasury securities

     

    $

    150,439

     

     

     

    $

     

    176,303

     

     

    Working capital

     

     

    137,116

     

     

     

     

    160,744

     

    Total assets

     

     

    191,271

     

     

     

     

    220,219

     

    Accumulated deficit

     

     

    (526,108

    )

     

     

     

    (497,894

    )

    Total stockholders' equity

     

     

    161,446

     

     

     

     

    186,609

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250506618710/en/

    Adicet Bio, Inc.

    Investor and Media Contacts

    Investors:

    Anne Bowdidge

    [email protected]

    Penelope Belnap

    Precision AQ

    212-362-1200

    [email protected]

    Media:

    Kerry Beth Daly

    [email protected]

    Get the next $ACET alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACET
    $APRE

    CompanyDatePrice TargetRatingAnalyst
    Adicet Bio Inc.
    $ACET
    9/30/2024$7.00Buy
    Guggenheim
    Adicet Bio Inc.
    $ACET
    9/11/2024Buy → Neutral
    H.C. Wainwright
    Adicet Bio Inc.
    $ACET
    6/27/2023Buy → Neutral
    Guggenheim
    Adicet Bio Inc.
    $ACET
    6/27/2023Mkt Outperform → Mkt Perform
    JMP Securities
    Adicet Bio Inc.
    $ACET
    6/1/2023$20.00 → $6.00Overweight → Neutral
    JP Morgan
    Adicet Bio Inc.
    $ACET
    9/21/2022$23.00Overweight
    JP Morgan
    Adicet Bio Inc.
    $ACET
    3/31/2022$28.00Outperform
    SMBC Nikko
    Adicet Bio Inc.
    $ACET
    3/8/2022$30.00Buy
    Truist Securities
    More analyst ratings

    $ACET
    $APRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

      SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)

      11/14/24 5:46:11 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

      SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)

      11/14/24 4:05:07 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

      SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)

      11/14/24 4:00:05 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    $APRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President/CEO Gilad Oren bought $10,110 worth of shares (5,500 units at $1.84), increasing direct ownership by 2% to 345,620 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      4/4/25 7:30:11 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President/CEO Gilad Oren bought $1,958 worth of shares (500 units at $3.92), increasing direct ownership by 0.15% to 333,395 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/24/24 8:30:13 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Duey Marc bought $131,700 worth of shares (30,000 units at $4.39), increasing direct ownership by 14% to 240,113 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/17/24 8:30:55 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    $APRE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

      Two programs with clinical data readouts in 2H/2025 Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary clinical data expected in 2H/2025; Trial now open for enrollment to patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) Preliminary data for ongoing ADI-270 Phase 1 clinical trial in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) expected in 2H/2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended M

      5/6/25 4:01:00 PM ET
      $ACET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on April 30, 2025. Three individuals were hired by Adicet in April 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 206,800 shares of Adicet's common stock with an exercise price of $0.66 per share, the closing price of Adicet's common stock as reported by Nasdaq on April 30, 2025. One-fourth of the shares underlying each employee's option will vest on the one-year anniversary of each recipient's start date and thereafter the remaining

      4/30/25 4:47:00 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

      Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from May 7-8, 2025 in New York. Details of the event are as follows: Date: Wednesday, May 7, 2025 Time: 1:30 p.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. i

      4/30/25 7:00:00 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    $APRE
    SEC Filings

    See more
    • SEC Form 10-Q filed by Adicet Bio Inc.

      10-Q - Adicet Bio, Inc. (0001720580) (Filer)

      5/6/25 4:07:37 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Adicet Bio, Inc. (0001720580) (Filer)

      5/6/25 4:04:06 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Adicet Bio Inc.

      DEFA14A - Adicet Bio, Inc. (0001720580) (Filer)

      4/29/25 4:09:13 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    $APRE
    Leadership Updates

    Live Leadership Updates

    See more
    • Adicet Bio Appoints Michael Grissinger to the Board of Directors

      --Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. "We are honored to welcome Michael to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "His extensive

      4/17/25 7:00:00 AM ET
      $ACET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

      Dr. Maltzman Brings Oncology and Autoimmune Experience in All Stages of Drug Development, from Early-Stage Research to Successful Regulatory Approvals and Commercialization Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Julie Maltzman, M.D. as Chief Medical Officer, effective January 13, 2025. Dr. Maltzman will lead the Adicet clinical development strategy to advance Adicet's robust autoimmune and oncology pipeline. "We are incredibly pleased to welcome Julie to the Adicet team. Her vast experience in successfully leading the c

      12/18/24 7:00:00 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

      DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe Pultar, MD as its senior medical advisor to support Aprea with developing and advancing APR-1051, Aprea's potential best in class WEE1 inhibitor. Dr. Pultar is a seasoned pharmaceutical executive with extensive experience in oncology, including the development of a WEE1 inhibitor (azenosertib) from early to late-stage clinical development. Dr. Pultar has vast experience in clinical development within both large and early-stag

      10/9/24 8:30:00 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    $APRE
    Financials

    Live finance-specific insights

    See more
    • Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

      Expanding clinical development of ADI-001 into autoimmune diseases following clearance of Investigational New Drug Application (IND); plan to initiate Phase 1 clinical study in 2Q 2024 Focusing enrollment on mantle cell lymphoma (MCL) in ongoing ADI-001 Phase 1 clinical trial given favorable complete response (CR) rate, durability, and safety ADI-001 clinical update expected 2H 2024 ADI-270 IND submission in renal cell carcinoma expected in 2Q 2024 Updated cash runway into 2H 2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, today provided corporate upda

      1/4/24 7:00:00 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

      Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a conference call and webcast presentation on Thursday, January 4, 2024 at 8:00am ET to provide an update on its clinical pipeline and corporate outlook. Conference Call and Webcast Event The live webcast of the presentation can be accessed by registering under "Presentations & Events" in the investors section of the Company's website at https://www.adicetbio.com. Upon registration, all participants will receive a confirmation email with a unique passcode to provide access to the webcast event. To

      1/3/24 4:01:00 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)

      ADI-001 demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels in patients with median 4 prior lines of therapy; 50% of patients enrolled had previously progressed on anti-CD19 chimeric antigen receptor T cell (CAR T) therapy 83% ORR and 67% CR rate observed in heavily pre-treated patients who had progressed on prior CAR T Six-month CR rate consistent with autologous CAR T cell therapy Favorable safety with no significant incidence of CRS (cytokine release syndrome) or ICANS (immune effector cell associated neurotoxicity syndrome) Robust pharmacokinetic profile in dose level 4 (DL4) with Cmax and Day 28 persistence exceeding approved

      6/26/23 4:00:00 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    $APRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim resumed coverage on Adicet Bio with a new price target

      Guggenheim resumed coverage of Adicet Bio with a rating of Buy and set a new price target of $7.00

      9/30/24 8:04:57 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Adicet Bio from Buy to Neutral

      9/11/24 7:31:19 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio downgraded by Guggenheim

      Guggenheim downgraded Adicet Bio from Buy to Neutral

      6/27/23 10:07:31 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    $APRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Grissinger Michael

      4 - Adicet Bio, Inc. (0001720580) (Issuer)

      4/21/25 4:11:32 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Grissinger Michael

      3 - Adicet Bio, Inc. (0001720580) (Issuer)

      4/21/25 4:09:52 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President/CEO Gilad Oren bought $10,110 worth of shares (5,500 units at $1.84), increasing direct ownership by 2% to 345,620 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      4/4/25 7:30:11 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care